Zynerba Pharmaceuticals (ZYNE) Receiving Somewhat Positive Media Coverage, Analysis Finds

Share

When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at 8.40%.

A number of brokerages recently weighed in on ZYNE. (ZYNE) now has a value of $6.67 while the company's 52 week low is at $8.25, the shares dropped to the 52 week low on 08/07/17. The stock has a consensus rating of Hold and an average target price of $20.00. Piper Jaffray had a markedly different take on 07/08/2017, proposing that ZYNE is now considered Neutral versus prior Overweight rating. Jefferies maintained the shares of ZYNE in report on Monday, June 26 with "Buy" rating. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of USA and worldwide trademark & copyright law.

About shares traded. Zynerba Pharmaceuticals Inc (ZYNE) has risen 161.36% since August 8, 2016 and is uptrending. Accern also assigned headlines about the company an impact score of 45.2667347720794 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Oppenheimer Holdings, Inc. set a $8.00 target price on Zynerba Pharmaceuticals, Inc.

Shares of Zynerba Pharma CS (NASDAQ:ZYNE) now have an Average Brokerage Recommendation of 1, number of Recs in ABR is 7 while industry rank of the company by ABR is 201 out of 265. The stock closing price is now trading downward to its 50 day moving average with change of -62.48%, tumbled to its 20 day moving average with figure of -61.33% and behind its 200 day moving average with value -62.90%.

More news: Maya Rudolph to play Ralphie's mom in Fox's 'A Christmas Story'

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! The stock has been active on the tape, now trading at $6.67, down from yesterday's close by -55.71%. Manatuck Hill Partners Llc acquired 71,400 shares as Amber Rd Inc (AMBR)'s stock declined 9.28%. The failure of ZYN002 improves the competitive landscape for GW and shares in the company were up slightly in morning trading, increasing to $119.10 apiece. H.C. Wainwright initiated the stock with "Buy" rating in Friday, October 7 report.

Analysts expect Infinera Corporation (NASDAQ:INFN) to report $ -0.13 EPS and has got OUTPERFORM rating from 6 of Thomson Reuters analysts and 0 analyst (s) given UNDERPERFORM rating. Following the purchase, the chairman now directly owns 336,012 shares in the company, valued at $6,619,436.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James E. Fickenscher purchased 5,200 shares of the firm's stock in a transaction that occurred on Friday, May 12th. The stock was purchased at an average cost of $19.82 per share, for a total transaction of $103,064.00. Following the completion of the transaction, the chief financial officer now directly owns 12,200 shares in the company, valued at $241,804. Institutional investors own 31.08% of the company's stock. Vanguard Group Inc. raised its position in Zynerba Pharmaceuticals by 53.9% in the first quarter.

Zynerba Pharma CS (NASDAQ:ZYNE) has trailing twelve month Return on Assets of 0%, which is key indicator of how profitable a company is relative to its total assets. The Firm is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs.

ZYN002 is the company's lead product candidate and is also being studied in Fragile X syndrome and osteoarthritis.

Like Zynerba Pharma's ZYN002 gel, Epidiolex contains cannabidiol (CBD), rather than the psychoactive component of cannabis, THC.

Share